Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 4/20 | 0.63 |
| ▸ | SI | P14410 | 2/20 | 0.57 |
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | LRAT | O95237 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11044942 | 1.00 | FUCA1 (0.63) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL18460913 | 1.00 | FUCA1 (0.63) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL21105130 | 1.00 | FUCA1 (0.63) | FUCA1SIGBA1MGAMGAA | |
| Bromide SCHEMBL6284958 | 0.96 | FUCA1 (0.60) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL5805992 | 0.96 | — | — | |
| SCHEMBL11049253 | 0.88 | — | — | |
| Carbamic Acid SCHEMBL6209325 | 0.85 | FUCA1 (0.50) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL29379044 | 0.83 | FUCA1 (0.55) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL374134 | 0.83 | FUCA1 (0.55) | FUCA1SIGBA1MGAMGAA | |
| SCHEMBL21105031 | 0.81 | GBA1 (0.50) | FUCA1SIGBA1MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1068 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106591401-A | Fermentation promoter for improving output of gentamycin C1a, and adding method thereof | 河南仁华生物科技有限公司 | 2017-04-26 | — | — | CN | claimed |
| EP-2069500-B1 | COMPOSITIONS COMPRISING A SIRNA AND LIPIDIC 4,5-DISUBSTITUTED 2-DEOXYSTREPTAMINE RING AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2014-09-24 | — | — | EP | claimed |
| CN-101918577-B | Novel aminoglycoside antibiotic, method for producing the same, and pharmaceutical use of the same | MEIJI SEIKA KAISHA | 2014-03-26 | — | — | CN | claimed |
| CN-101918577-A | Novel aminoglycoside antibiotic, method for producing the same, and pharmaceutical use of the same | MEIJI SEIKA KAISHA | 2010-12-15 | — | — | CN | claimed |
| US-20100311680-A1 | SYNTHESIS OF NOVEL NEAMINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS | UNIVERSITE JOSEPH FOURIER (FR) | 2010-12-09 | — | — | US | claimed |
| EP-2235031-A2 | SYNTHESIS OF NOVEL NEAMINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS | Université Joseph Fourier (FR) | 2010-10-06 | — | — | EP | claimed |
| CN-101772347-A | The 2-amino-2 of sense single stranded rna enveloped virus, the two deoxidation-α of 7--D-glycerol-D-glucose-pyrans heptose base inhibitor | INST HEPATITIS & VIRUS RES | 2010-07-07 | — | — | CN | claimed |
| EP-2197451-A1 | 2-AMINO-2,7-DIDEOXY-ALPHA-D-GLYCERO-D-GLUCO-HEPTOPYRANOSYL INHIBITORS OF POSITIVE SENSE SINGLE-STRANDED RNA ENVELOPE VIRUSES | Institute For Hepatitis And Virus Research (US) | 2010-06-23 | — | — | EP | claimed |
| US-20100035974-A1 | COMPOSITIONS COMPRISING A SIRNA AND LIPIDIC 4,5-DISUBSTITUTED 2-DEOXYSTREPTAMINE RING AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2010-02-11 | — | — | US | claimed |
| WO-2009095588-A2 | SYNTHESIS OF NOVEL NEAMINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS | UNIVERSITE JOSEPH FOURIER (FR) | 2009-08-06 | — | — | WO | claimed |
| US-4424344-A | 2-N-Acylated and 2-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides and process | ELI LILLY AND COMPANY (US) | 1984-01-03 | — | — | US | claimed |
| EP-0048614-A1 | 1-N-acylated and 1-N-alkylated derivatives of 4-0-substituted -2-deoxystreptamine aminoglycosides | ELI LILLY AND COMPANY (US) | 1982-03-31 | — | — | EP | claimed |
| EP-0048613-A1 | 4-0-Substituted -2-deoxystreptamine aminoglycoside derivatives, their preparation and formulations containing them | ELI LILLY AND COMPANY (US) | 1982-03-31 | — | — | EP | claimed |
| US-4212860-A | COUPLING THE PENTOFURANOSYL ONTO THE PROTECTED CYCLITOL | SCHERING CORPORATION (US) | 1980-07-15 | — | — | US | claimed |
| US-4171356-A | 2-Unsubstituted derivatives of 4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitois, methods for their use as antibacterial agents and compositions useful therefor | SCHERING CORPORATION (US) | 1979-10-16 | — | — | US | claimed |
| US-4170641-A | 1-N-(ω-aminoalkanesulfonyl) derivative of aminoglycosidic antibiotic and process for preparation thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 1979-10-09 | — | — | US | claimed |
| US-4125707-A | ANTIBIOTIC | SOCIETA' FARMACEUTICI ITALIA S.P.A. (IT) | 1978-11-14 | — | — | US | claimed |
| US-4085208-A | Process for preparing 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and novel 1-epimers and 1-N-alkyl derivatives produced thereby; methods for the use of the 1-epimer derivatives as antibacterial agents and compositions useful therefor | SCHERING CORPORATION (US) | 1978-04-18 | — | — | US | claimed |
| US-4062947-A | Di-N-alkylaminoglycosides, methods for their manufacture and novel intermediates useful therein, method for their use as antibacterial agents and pharmaceutical compositions useful therefor | SCHERING CORPORATION (US) | 1977-12-13 | — | — | US | claimed |
| US-3982996-A | CULTURING | STERLING DRUG INC. (US) | 1976-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311680-A1 | SYNTHESIS OF NOVEL NEAMINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS | HRH3, HRH4, H1-4 | FUCA1 4799/4885SI 3165/4885GBA1 4069/4885 |
| US-20100035974-A1 | COMPOSITIONS COMPRISING A SIRNA AND LIPIDIC 4,5-DISUBSTITUTED 2-DEOXYSTREPTAMINE RING AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF | STARD3, NSUN3, NR1H4 | FUCA1 2564/4885SI 3188/4885GBA1 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.